Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Beone Medicines Ltd. (ONC) since 2016 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Beone Medicines Ltd.. (See page 1 of this report.) Table 2 shows the detailed insider transactions. This company's CIK number is 1651308.
Total stock buying since 2016: $948,079,384.
Total stock sales since 2016: $6,175,553,111.
Total stock option exercises since 2016: $70,516,106.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2025 | 0 | $0 | 1,456,704 | $375,332,844 | 2,336,986 | $47,980,297 |
| 2024 | 0 | $0 | 19,117,537 | $3,815,653,609 | 1,380,221 | $1,171,436 |
| 2023 | 0 | $0 | 4,260,548 | $801,862,198 | 67,635 | $8,792 |
| 2022 | 0 | $0 | 120,062 | $21,381,114 | 1,233,947 | $3,566,106 |
| 2021 | 165,529 | $50,000,020 | 1,552,008 | $463,535,154 | 105,003 | $4,906,771 |
| 2020 | 0 | $0 | 2,361,950 | $530,233,023 | 1,559,200 | $7,421,383 |
| 2019 | 0 | $0 | 295,150 | $45,912,136 | 133,625 | $3,059,078 |
| 2018 | 7,794,298 | $827,922,798 | 272,012 | $39,141,595 | 108,000 | $2,328,468 |
| 2017 | 176,056 | $12,499,976 | 1,180,611 | $73,572,490 | 2,500 | $73,775 |
| 2016 | 11,085,495 | $57,656,590 | 286,057 | $8,928,948 | 0 | $0 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2021-08-05 | Oyler John (Chief Executive Officer) | Sale | 44,462 | 317.25 | 14,105,702 |
| 2021-08-04 | Oyler John (Chief Executive Officer) | Sale | 80,847 | 309.36 | 25,010,666 |
| 2021-08-03 | Oyler John (Chief Executive Officer) | Sale | 83,359 | 318.02 | 26,509,912 |
| 2021-07-22 | Oyler John (Chief Executive Officer) | Sale | 69,216 | 293.13 | 20,289,147 |
| 2021-07-21 | Oyler John (Chief Executive Officer) | Sale | 27,160 | 280.66 | 7,622,671 |
| 2021-07-20 | Oyler John (Chief Executive Officer) | Sale | 43,695 | 277.41 | 12,121,255 |
| 2021-07-15 | Huang Jane (CMO, Hematology) | Sale | 21,000 | 333.21 | 6,997,452 |
| 2021-07-15 | Huang Jane (CMO, Hematology) | Option Ex | 21,000 | 151.60 | 3,183,537 |
| 2021-07-08 | Oyler John (Chief Executive Officer) | Sale | 67,181 | 298.70 | 20,067,166 |
| 2021-07-07 | Oyler John (Chief Executive Officer) | Sale | 66,746 | 311.36 | 19,864,323 |
| 2021-07-06 | Wu Xiaobin (President, COO & GM China) | Sale | 10,180 | 326.45 | 3,323,271 |
| 2021-07-06 | Oyler John (Chief Executive Officer) | Sale | 57,375 | 296.19 | 16,994,130 |
| 2021-06-18 | Wang Lai (Global Head of R&D) | Sale | 802 | 331.15 | 265,583 |
| 2021-06-18 | Wu Xiaobin (President, COO & GM China) | Sale | 1,156 | 330.93 | 382,550 |
| 2021-06-18 | Huang Jane (CMO, Hematology) | Sale | 469 | 325.66 | 152,733 |
| 2021-06-18 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 486 | 325.89 | 158,383 |
| 2021-06-10 | Chen Timothy Yung-cheng | Sale | 2,836 | 352.07 | 998,473 |
| 2021-06-10 | Chen Timothy Yung-cheng | Option Ex | 2,836 | 31.59 | 89,589 |
| 2021-06-09 | Chen Timothy Yung-cheng | Sale | 3,164 | 351.62 | 1,112,532 |
| 2021-06-09 | Chen Timothy Yung-cheng | Option Ex | 3,164 | 31.59 | 99,950 |
| 2021-06-07 | Wu Xiaobin (President, COO & GM China) | Sale | 3,398 | 352.47 | 1,197,706 |
| 2021-06-07 | Huang Jane (CMO, Hematology) | Sale | 603 | 351.55 | 211,985 |
| 2021-06-07 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 650 | 354.16 | 230,202 |
| 2021-05-10 | Wang Xiaodong | Sale | 3,394 | 301.23 | 1,022,367 |
| 2021-05-10 | Wang Xiaodong | Option Ex | 47,503 | .13 | 6,175 |
| 2021-05-03 | Wu Xiaobin (President, COO & GM China) | Sale | 6,715 | 343.00 | 2,303,245 |
| 2021-04-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 354.48 | 531,712 |
| 2021-04-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2021-03-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 324.25 | 486,370 |
| 2021-03-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2021-02-26 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 319.27 | 478,906 |
| 2021-02-26 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2021-01-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 324.17 | 486,255 |
| 2021-01-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2021-01-15 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 12,600 | 344.96 | 4,346,496 |
| 2021-01-15 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 12,600 | 6.50 | 81,900 |
| 2021-01-14 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 1,400 | 344.72 | 482,605 |
| 2021-01-14 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 1,400 | 6.50 | 9,100 |
| 2021-01-04 | Baker Julian (Director) | Sale | 121,154 | 220.50 | 26,714,457 |
| 2020-12-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 248.87 | 373,303 |
| 2020-12-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-12-14 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 91,900 | 228.58 | 21,006,134 |
| 2020-12-14 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 1,497,200 | 3.50 | 5,240,200 |
| 2020-12-04 | Baker Julian (Director) | Sale | 1,511,546 | 220.50 | 333,295,893 |
| 2020-11-30 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 268.94 | 403,408 |
| 2020-11-30 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-10-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 300.70 | 451,045 |
| 2020-10-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-10-16 | Wang Xiaodong | Sale | 5,000 | 320.00 | 1,600,000 |
| 2020-10-05 | Wu Xiaobin (President & GM China) | Sale | 4,000 | 300.00 | 1,200,000 |
| 2020-10-05 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 14,000 | 298.89 | 4,184,460 |
| 2020-10-05 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 14,000 | 6.50 | 91,000 |
| 2020-10-05 | Wang Xiaodong | Sale | 5,000 | 300.00 | 1,500,000 |
| 2020-09-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 280.16 | 420,242 |
| 2020-09-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-09-29 | Oyler John (Chief Executive Officer) | Sale | 23,303 | 278.75 | 6,495,618 |
| 2020-09-28 | Oyler John (Chief Executive Officer) | Sale | 31,000 | 280.38 | 8,691,873 |
| 2020-09-25 | Wu Xiaobin (President & GM China) | Sale | 4,000 | 280.35 | 1,121,408 |
| 2020-09-25 | Wang Xiaodong | Sale | 5,000 | 280.82 | 1,404,095 |
| 2020-09-17 | Wu Xiaobin (President & GM China) | Sale | 4,000 | 260.72 | 1,042,867 |
| 2020-09-17 | Wang Xiaodong | Sale | 5,000 | 260.69 | 1,303,454 |
| 2020-09-16 | Oyler John (Chief Executive Officer) | Sale | 27,275 | 255.91 | 6,979,999 |
| 2020-09-15 | Oyler John (Chief Executive Officer) | Sale | 34,214 | 254.78 | 8,716,974 |
| 2020-09-14 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 14,000 | 250.27 | 3,503,766 |
| 2020-09-14 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 14,000 | 6.50 | 91,000 |
| 2020-09-14 | Oyler John (Chief Executive Officer) | Sale | 19,739 | 250.05 | 4,935,717 |
| 2020-09-03 | Huang Jane (CMO, Hematology) | Sale | 3,128 | 233.64 | 730,829 |
| 2020-09-02 | Oyler John (Chief Executive Officer) | Sale | 27,807 | 229.83 | 6,390,994 |
| 2020-09-01 | Oyler John (Chief Executive Officer) | Sale | 20,274 | 235.15 | 4,767,512 |
| 2020-08-31 | Oyler John (Chief Executive Officer) | Sale | 12,961 | 240.53 | 3,117,457 |
| 2020-08-28 | Huang Jane (CMO, Hematology) | Sale | 3,000 | 242.37 | 727,104 |
| 2020-08-28 | Huang Jane (CMO, Hematology) | Option Ex | 3,000 | 29.49 | 88,470 |
| 2020-08-21 | Oyler John (Chief Executive Officer) | Sale | 40,788 | 240.72 | 9,818,364 |
| 2020-08-20 | Oyler John (Chief Executive Officer) | Sale | 21,523 | 233.80 | 5,032,012 |
| 2020-08-19 | Oyler John (Chief Executive Officer) | Sale | 29,866 | 234.76 | 7,011,222 |
| 2020-08-14 | Oyler John (Chief Executive Officer) | Sale | 8,705 | 211.82 | 1,843,866 |
| 2020-08-13 | Oyler John (Chief Executive Officer) | Sale | 14,443 | 213.72 | 3,086,815 |
| 2020-08-12 | Chen Timothy Yung-cheng | Sale | 2,897 | 212.00 | 614,164 |
| 2020-08-12 | Chen Timothy Yung-cheng | Option Ex | 2,897 | 31.59 | 91,516 |
| 2020-08-12 | Oyler John (Chief Executive Officer) | Sale | 19,820 | 211.82 | 4,198,272 |
| 2020-08-11 | Chen Timothy Yung-cheng | Sale | 1,903 | 213.41 | 406,119 |
| 2020-08-11 | Chen Timothy Yung-cheng | Option Ex | 1,903 | 31.59 | 60,115 |
| 2020-08-10 | Wang Xiaodong | Sale | 4,000 | 212.35 | 849,396 |
| 2020-08-10 | Chen Timothy Yung-cheng | Sale | 2,200 | 214.46 | 471,812 |
| 2020-08-10 | Chen Timothy Yung-cheng | Option Ex | 2,200 | 31.59 | 69,498 |
| 2020-08-05 | Oyler John (Chief Executive Officer) | Sale | 17,254 | 223.20 | 3,851,041 |
| 2020-08-04 | Oyler John (Chief Executive Officer) | Sale | 15,383 | 221.28 | 3,403,904 |
| 2020-08-03 | Oyler John (Chief Executive Officer) | Sale | 25,176 | 220.02 | 5,539,248 |
| 2020-07-29 | Huang Jane (CMO, Hematology) | Sale | 3,000 | 210.93 | 632,796 |
| 2020-07-29 | Huang Jane (CMO, Hematology) | Option Ex | 3,000 | 94.94 | 284,835 |
| 2020-07-22 | Oyler John (Chief Executive Officer) | Sale | 27,748 | 241.54 | 6,702,307 |
| 2020-07-21 | Oyler John (Chief Executive Officer) | Sale | 26,413 | 251.88 | 6,652,906 |
| 2020-07-20 | Wu Xiaobin (President & GM China) | Sale | 2,600 | 250.16 | 650,408 |
| 2020-07-20 | Wang Xiaodong | Sale | 17,000 | 251.50 | 4,275,517 |
| 2020-07-20 | Oyler John (Chief Executive Officer) | Sale | 28,762 | 251.56 | 7,235,282 |
| 2020-07-17 | Wu Xiaobin (President & GM China) | Sale | 700 | 245.02 | 171,513 |
| 2020-07-15 | Wu Xiaobin (President & GM China) | Sale | 2,700 | 243.19 | 656,599 |
| 2020-07-13 | Wu Xiaobin (President & GM China) | Sale | 3,000 | 220.00 | 660,000 |
| 2020-07-08 | Oyler John (Chief Executive Officer) | Sale | 17,529 | 200.30 | 3,510,988 |
| 2020-07-07 | Huang Jane (CMO, Hematology) | Sale | 3,921 | 200.00 | 784,200 |
| 2020-07-07 | Huang Jane (CMO, Hematology) | Option Ex | 3,921 | 160.40 | 628,928 |
| 2020-07-07 | Wang Xiaodong | Sale | 6,000 | 200.00 | 1,200,000 |
| 2020-07-07 | Oyler John (Chief Executive Officer) | Sale | 19,023 | 198.38 | 3,773,725 |
| 2020-07-06 | Oyler John (Chief Executive Officer) | Sale | 17,362 | 196.95 | 3,419,480 |
| 2020-07-01 | Wang Xiaodong | Sale | 4,847 | 190.83 | 924,962 |
| 2020-07-01 | Oyler John (Chief Executive Officer) | Sale | 3,816 | 191.59 | 731,122 |
| 2020-06-29 | Huang Jane (CMO, Hematology) | Sale | 1,935 | 191.16 | 369,896 |
| 2020-06-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-06-29 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 300 | 191.23 | 57,368 |
| 2020-06-29 | Oyler John (Chief Executive Officer) | Sale | 1,435 | 192.69 | 276,515 |
| 2020-06-26 | Huang Jane (CMO, Hematology) | Sale | 2,079 | 200.29 | 416,396 |
| 2020-06-26 | Huang Jane (CMO, Hematology) | Option Ex | 2,079 | 160.40 | 333,471 |
| 2020-06-24 | Oyler John (Chief Executive Officer) | Sale | 14,381 | 187.71 | 2,699,399 |
| 2020-06-23 | Wang Xiaodong | Sale | 6,000 | 186.52 | 1,119,108 |
| 2020-06-23 | Oyler John (Chief Executive Officer) | Sale | 15,070 | 186.52 | 2,810,916 |
| 2020-06-22 | Wang Xiaodong | Sale | 5,000 | 181.95 | 909,745 |
| 2020-06-22 | Oyler John (Chief Executive Officer) | Sale | 10,281 | 181.68 | 1,867,800 |
| 2020-06-10 | Oyler John (Chief Executive Officer) | Sale | 900 | 175.07 | 157,563 |
| 2020-06-08 | Wu Xiaobin (President & GM China) | Sale | 2,800 | 171.07 | 478,990 |
| 2020-06-08 | Huang Jane (CMO, Hematology) | Sale | 631 | 170.84 | 107,800 |
| 2020-06-08 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 453 | 170.84 | 77,390 |
| 2020-06-08 | Wang Xiaodong | Sale | 6,000 | 171.46 | 1,028,730 |
| 2020-05-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 163.91 | 245,863 |
| 2020-05-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-05-19 | Glazer Donald W. | Sale | 10,000 | 169.84 | 1,698,400 |
| 2020-05-01 | Wu Xiaobin (President & GM China) | Sale | 7,024 | 141.92 | 996,832 |
| 2020-05-01 | Oyler John (Chief Executive Officer) | Sale | 4,635 | 141.90 | 657,697 |
| 2020-04-29 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 162.30 | 243,450 |
| 2020-04-29 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-04-16 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 160.00 | 240,000 |
| 2020-04-16 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-03-04 | Wang Xiaodong | Sale | 5,000 | 157.65 | 788,259 |
| 2020-02-18 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 170.57 | 255,862 |
| 2020-02-18 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2020-01-21 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 171.24 | 256,852 |
| 2020-01-21 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2019-12-17 | Oyler John (Chief Executive Officer) | Sale | 62,259 | 161.65 | 10,063,980 |
| 2019-12-16 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 167.56 | 251,334 |
| 2019-12-16 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2019-11-18 | Huang Jane (CMO, Hematology) | Sale | 1,500 | 195.13 | 292,689 |
| 2019-11-18 | Huang Jane (CMO, Hematology) | Option Ex | 1,500 | 29.49 | 44,235 |
| 2019-11-18 | Liang Howard (CFO & Chief Strategy Officer) | Sale | 25,000 | 195.17 | 4,879,175 |
| 2019-11-18 | Liang Howard (CFO & Chief Strategy Officer) | Option Ex | 25,000 | 6.50 | 162,500 |
| 2019-11-15 | Wu Xiaobin (President & GM China) | Sale | 1,000 | 202.05 | 202,050 |
| 2019-11-15 | Wang Xiaodong | Sale | 1,891 | 202.05 | 382,076 |
| 2019-11-14 | Wang Xiaodong | Sale | 11,109 | 193.98 | 2,154,901 |
| 2019-11-05 | Chen Timothy Yung-cheng | Sale | 3,800 | 188.99 | 718,169 |
| 2019-11-05 | Chen Timothy Yung-cheng | Option Ex | 4,000 | 41.01 | 164,040 |
| 2019-11-04 | Huang Jane (CMO, Hematology) | Sale | 32,900 | 190.96 | 6,282,715 |
| 2019-11-04 | Huang Jane (CMO, Hematology) | Option Ex | 32,900 | 29.49 | 970,221 |
Insider trading activities including stock purchases, stock sales, and option exercises of ONC listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Beone Medicines Ltd. (symbol ONC, CIK number 1651308) see the Securities and Exchange Commission (SEC) website.